SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

GERN

Geron Corporation
MIXED
Impact 6/10
Horizonweeks Processed12d 19h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor Q4 2026 revenue trajectory for RYTELO to see if demand growth sustains the 10% QoQ pace; watch for European launch uptake in Germany and France as a second growth leg; the IMpactMF discontinuation removes a key pipeline catalyst, increasing reliance on LR-MDS commercial execution.

DirectionMixed
Confidencehigh
Horizonweeks

RYTELO

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially available (first commercial launch in Q3 2024)
Next catalyst
None dated

What to watchWatch the Q3 2026 earnings release on Nov 4, 2026 (consensus ~$60.4M revenue). The key question is whether RYTELO's revenue growth trajectory can accelerate from the ~11% QoQ pace, which would validate the revenue ramp thesis behind the $4+ analyst targets. The 7.39 days-to-cover short interest adds a squeeze potential if results surprise positively, but the shareholder lawsuit and high short volume ratio suggest significant skepticism about the commercial ramp.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.08
T+0 close · Nov 4, 2026 · via day close
Latest settled
−5.56%
T+5 · $1.02 · next T+20 in 16d
Vs SPY
−4.64%
α at T+5
Latest observation
−11.57%
T+8 · FF3 residual α
  1. T+0 · Nov 4 $1.08entry
  2. T+1 · 12d ago −12.03%α −7.62% · $0.9501
  3. T+5 · 6d ago −5.56%α −4.64% · $1.02
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Geron reported Q3 2026 RYTELO net product revenue of $60.1M, beating the $60.4M consensus by a slight margin, and achieved net income of $1.4M ($0.00 per share) versus consensus EPS of -$0.01. The company reiterated its 2026 revenue guidance at the mid-to-high end of $220M-$240M and lowered its operating expense range to $220M-$230M. However, the discontinuation of the Phase 3 IMpactMF trial in myelofibrosis removes a key pipeline catalyst and increases reliance on the LR-MDS franchise.

Key Financial Metrics

EPS
$0.00
est −$0.01 · +100.0%
Revenue
$60.2M
est $60.4M · -0.3% · +27.4% YoY
Rating
beat
Guidance
$220M-$240M
maintained

Key Facts

  • Q3 2026 RYTELO net product revenue $60.1M, up 5% QoQ and 27% YoY from $47.2M
  • Net income of $1.4M ($0.00 per share) vs net loss of $18.4M ($0.03) in Q3 2025
  • Total operating expenses fell to $54.4M from $61.1M YoY
  • 2026 revenue guidance maintained at mid-to-high end of $220M-$240M
  • 2026 total operating expense guidance lowered to $220M-$230M from $230M-$240M
  • Phase 3 IMpactMF trial in myelofibrosis discontinued after DMC deemed unlikely to meet primary OS endpoint
  • Cash and marketable securities $339.4M as of Sep 30, 2026, up from $326.9M at Jun 30, 2026
  • Initiated gated European commercial launch; Germany availability expected by end of 2026

Financial Impact

Q3 revenue $60.1M slightly below $60.4M consensus; EPS $0.00 vs -$0.01 consensus beat; operating expenses lowered by $10M; pipeline setback eliminates potential future revenue stream

revenueepsoperating expensespipeline value

Risk Factors

  • Discontinuation of Phase 3 IMpactMF trial eliminates a potential future revenue stream and increases dependency on LR-MDS
  • Revenue guidance maintained at mid-to-high end of $220M-$240M implies Q4 revenue of $50.6M-$70.6M, a wide range
  • European commercial launch is early stage with pricing, reimbursement and competitive risks
  • Cash burn remains negative on an operating basis despite net income due to non-cash items

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395186

Track record

11 reports on GERN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $0.9742 Now $0.9400 −3.51% settles Nov 17
  2. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $0.9965 to $0.9419 Now $0.9400 −5.67% ▼ −5.48% −3.79% vs SPY
  3. Nov 4, 202612d ago 8-K Mixed 6/10 No price data
  4. Nov 4, 202612d ago Press Release Mixed 6/10 Viewing Entry $1.08 to $1.02 Now $0.9400 −12.96% ▼ −5.56% −4.64% vs SPY
  5. Oct 28, 202619d ago 8-K Bearish 6/10 Entry $0.9462 to $0.9501 Now $0.9400 +0.66% ▼ −0.41% −5.14% vs SPY
  6. Oct 19, 202628d ago Press Release Neutral 2/10 Entry $1.24 to $1.16 Now $0.9400 −24.19% ▼ −6.85% −6.88% vs SPY
  7. Sep 18, 20268w ago Press Release Neutral 2/10 Entry $1.30 to $1.25 Now $0.9400 −27.69% ▼ −3.85% −2.83% vs SPY
  8. Apr 22, 202629w ago Press Release Neutral 1/10 Entry $1.55 to $1.52 Now $0.9400 −39.35% ▼ −2.26% −2.31% vs SPY
  9. Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $1.71 to $1.69 Now $0.9400 −45.03% ▼ −1.17% −4.69% vs SPY
  10. Mar 30, 202633w ago Court Ruling Neutral 2/10 Entry $1.41 to $1.74 Now $0.9400 −33.33% ▲ +23.40% +19.10% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026